Reducing Errors in Identification of von Willebrand Disease: The Experience of the Royal College of Pathologists of Australasia Quality Assurance Program

ABSTRACT

Regular multilaboratory surveys of laboratories derived primarily from Australia, New Zealand, and Southeast Asia have been conducted during the last 8 years to evaluate testing proficiency in the diagnosis of von Willebrand disease (vWD). We summarize and update the findings of these surveys with a particular emphasis on diagnostic errors and error rates associated with particular tests or test panel limitations. A total of 43 plasma samples have been dispatched to survey participants. These have included 13 normal samples, five type 1 vWD samples, eight type 2 vWD samples (three 2A, three 2B, one 2M, and one 2N), and four type 3 vWD samples. In addition to numerical test results, participant laboratories (currently, n = 49) were asked to provide diagnostic interpretations regarding results, and whether or not vWD was suggested, and if so, a probable subtype. Although laboratories usually provided correct interpretative responses, diagnostic errors occurred in a substantial number of cases. On average, type 1 vWD plasma was misidentified as type 2 vWD in 13.3% of cases, and laboratories performing von Willebrand factor (vWF):ristocetin cofactor activity (RCo) without vWF:collagen-binding activity (CB) were seven times more likely to make such an error compared with those performing vWF:CB. Similarly, type 2 vWD plasma was misidentified as type 1 or type 3 vWD in an average of 20.1% of cases, and laboratories performing vWF:RCo without vWF:CB were three times more likely to make such an error compared with those performing vWF:CB. Finally, normal plasma was misidentified as vWD in an average of 6.7% of cases, and laboratories performing vWF:RCo without vWF:CB were four times more likely to make such an error compared with those performing vWF:CB. We conclude that although laboratories are generally proficient in tests for vWD, diagnostic errors do occur and error rates are substantially reduced when test panels are more comprehensive and include the vWF:CB.

von Willebrand factor (vWF) - von Willebrand disorder - von Willebrand disease (vWD) - laboratory assessment - survey - hemostasis testing - diagnostic practice - quality control - quality assurance

REFERENCES

• 1 Sadler J E, Mannucci P M, Berntorp E et al.. Impact, diagnosis and treatment of von Willebrand Disease.  Thromb Haemost. 2000;  84 160-174
• 2 Sadler J E, Gralnick H R. Commentary: a new classification for von Willebrand Disease.  Blood. 1994;  84 676-679
• 3 Sadler J E. A revised classification of von Willebrand Disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis.  Thromb Haemost. 1994;  71 520-525
• 4 Favaloro E J. Appropriate laboratory assessment as a critical facet in the proper diagnosis and sub-classification of von Willebrand's disorder.  Baillieres Best Pract Res Clin Haematol. 2001;  14 299-319
• 5 Favaloro E J. Laboratory assessment as a critical component of the appropriate diagnosis and sub-classification of von Willebrand's disease.  Blood Rev. 1999;  13 185-204
• 6 Favaloro E J. von Willebrand factor (VWF) collagen binding (activity) assay (VWF:CBA) in the diagnosis of von Willebrand's disorder (VWD): a 15-year journey.  Semin Thromb Hemost. 2002;  28 191-202
• 7 Favaloro E J. Laboratory identification of von Willebrand disease: technical and scientific perspectives.  Semin Thromb Hemost. 2006;  32 456-471
• 8 Favaloro E J, Smith J, Petinos P, Collecutt M, Street A, Hertzberg M. on behalf of the RCPA Quality Assurance Program (QAP) in Haematology Scientific Haemostasis Advisory Panel . Laboratory testing, diagnosis and management of von Willebrand's disease: Current practice in Australasia.  Am J Clin Pathol. 1999;  112 712-719
• 9 Favaloro E J, Smith J, Petinos P, Hertzberg M, Koutts J. on behalf of the RCPA Quality Assurance Program (QAP) in Haematology Haemostasis Scientific Advisory Panel . Laboratory testing for von Willebrand's disease: an assessment of current diagnostic practice and efficacy by means of a multi-laboratory survey.  Thromb Haemost. 1999;  82 1276-1282
• 10 Favaloro E J, Thom J, Baker R. on behalf of the Australasian Society for Thrombosis and Haemostasis Emerging Technologies Group . Assessment of current diagnostic practice and efficacy in testing for von Willebrand's disease: results from the second Australasian laboratory survey.  Blood Coagul Fibrinolysis. 2000;  11 729-738
• 11 Favaloro E J, Bonar R, Sioufi J et al.. (on behalf of the RCPA QAP in Haematology Haemostasis Committee). Laboratory diagnosis of von Willebrand Disorder: current practice in the Southern Hemisphere.  Am J Clin Pathol. 2003;  119 882-893
• 12 Favaloro E J, Bonar R, Kershaw G et al.. (on behalf of the RCPA QAP in Haematology). Laboratory diagnosis of von Willebrand Disorder: quality and diagnostic improvements driven by peer review in a multi-laboratory test process.  Haemophilia. 2004;  10 232-242
• 13 Favaloro E J, Bonar R, Kershaw G et al.. (on behalf of the RCPA QAP in Haematology). Laboratory diagnosis of von Willebrand Disorder: use of multiple functional assays reduces diagnostic error rates.  Lab Hematol. 2005;  11 91-97
• 14 Haematology R CPA. QAP contact and program details. Available at: http://www.rcpaqap.com.au/ Accessed February 2, 2006
• 15 Favaloro E J. A duplex issue: (i) time to re-appraise the diagnosis and classification of von Willebrand disorder (VWD), and (ii) clarification of the roles of von Willebrand factor (VWF) collagen binding and ristocetin cofactor activity assays.  Haemophilia. 2002;  8 828-831
• 16 Casonato A, Pontara E, Bertomoro A, Sartorello F, Cattini M G, Girolami A. Von Willebrand factor collagen binding activity in the diagnosis of von Willebrand disease: an alternative to ristocetin cofactor activity?.  Br J Haematol. 2001;  112 578-583
• 17 Meijer P, Haverkate F. An external quality assessment programme for von Willebrand factor laboratory analysis: an overview from the European Concerted Action on Thrombosis and Disabilities Foundation.  Semin Thromb Hemost. 2006;  32 485-491
• 18 NEQAS QAP program .United Kingdom National External Quality Assessment Service. Available at: http://www.ukneqas.org.uk/ Accessed February 2, 2006
• 19 Jennings I, Kitchen S, Kitchen D, Woods T AL, Preston F E. Von Willebrand factor measurement in the UK NEQAS proficiency testing program.  J Thromb Haemost. 2003;  (suppl 1: abst P0108)
• 20 Kitchen S, Jennings I, Woods T AL, Kitchen D P, Walker I D, Preston F E. Laboratory tests for measurement of von Willebrand factor show poor agreement among different centers: results from the United Kingdom National External Quality Assessment Scheme for Blood Coagulation.  Semin Thromb Hemost. 2006;  32 492-498
• 21 Shahangian S, Stankovi A K, Lubin I M, Handsfield J H, White M D. Results of the Survey of Hospital Coagulation Laboratory Practices, United States-2001. Available at: http://www.phppo.cdc.gov/mlp/coag2001.aspx Accessed February 2, 2006
• 22 CAP QAP program details. Available at: http://www.cap.org/apps/cap.portal Accessed on February 2, 2006
• 23 Hayes T E, Brandt J T, Chandler W L et al.. External peer review quality assurance testing in von Willebrand disease: the recent experience of the United States College of American Pathologists Proficiency Testing Program.  Semin Thromb Hemost. 2006;  32 499-504
• 24 ECAT QAP program details. Available at: http://www.ecat.nl/ Accessed February 2, 2006